{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:39:01Z","timestamp":1761093541248,"version":"build-2065373602"},"reference-count":199,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T00:00:00Z","timestamp":1327363200000},"content-version":"vor","delay-in-days":10792,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1982,7,8]]},"abstract":"<jats:p>Cefoperazone is a parenteral cephalosporin antibiotic that is pending approval by the U. S. Food and Drug Administration. Compared to most other cephalosporins cefoperazone has a greatly expanded spectrum of bactericidal activity that encompasses most aerobic gram\u2010positive bacteria except entero\u2010cocci, most aerobic gram\u2010negative bacteria, including a majority of <jats:italic>Pseudomonas aeruginosa<\/jats:italic> strains, and a number of pathogenic anaerobic bacteria. Its long serum half\u2010life, approximately two hours, permits a twelve hourly dosing schedule. No dosage modification is required in patients with renal insufficiency, and only minor modification is needed in patients with hepatic insufficiency or biliary obstruction. Clinical trials have established cefoperazone's efficacy in lower respiratory tract infections, urinary tract infections, and a variety of other bacterial infections. Adverse reactions have been infrequent, and few serious reactions have been identified. Cefoperazone is a promising new agent for the treatment of gram\u2010negative bacillary and polymicrobial infections, especially in settings that require empiric therapy.<\/jats:p>","DOI":"10.1002\/j.1875-9114.1982.tb03186.x","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T19:48:10Z","timestamp":1450295290000},"page":"185-196","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antimicrobial Activity, Pharmacokinetics, Adverse Reactions, and Therapeutic Indications of Cefoperazone"],"prefix":"10.1002","volume":"2","author":[{"given":"Elizabeth A.","family":"Funk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Strausbaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.1.195"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.5.533"},{"key":"e_1_2_1_4_2","unstructured":"JonesRN.The microbiology of cefoperazone: An overview (abstract). In:Scientific program and abstracts. Empiric therapy of bacterial infections: A cefoperazone symposium. Geneva Switzerland 1981."},{"key":"e_1_2_1_5_2","first-page":"103","article-title":"Microbiological evaluation of cefoperazone, a new semisynthetic cephalosporin","volume":"3","author":"Blandino G","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.2.150"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237999"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.5.549"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.6.731"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198122060-00002"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.4.736"},{"key":"e_1_2_1_12_2","first-page":"39","article-title":"Cefoperazone: Evaluation of the in vitro activity and an analysis of the disk diffusion test","volume":"3","author":"Thornsberry C","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_13_2","first-page":"149","article-title":"A study of the in vitro activity of cefoperazone: A comparison with other beta\u2010lactam antibiotics","volume":"3","author":"Wise R","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.423"},{"key":"e_1_2_1_15_2","unstructured":"GibbsDL FayD.A multicenter evaluation of the cefoperazone disk susceptibility test (abstract 751). In: Program and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago 1981."},{"key":"e_1_2_1_16_2","unstructured":"GerlachEH JohnsonKS RaymonJL.Detection of susceptibility to third generation cephalosporins using cefoperazone MIC results (abstract 762). See reference 14."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.488"},{"key":"e_1_2_1_18_2","first-page":"89","article-title":"In vitro activity of a new semisynthetic cephalosporin: cefoperazone","volume":"3","author":"Aukenthaler R","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.6.893"},{"key":"e_1_2_1_20_2","unstructured":"SimardP BergeronMG.Inoculum size effect on the MIC of cefoperazone and other cephalosporins against 118 strains of Haemophilus Influenzae (abstract 761). In: Abstracts of the Twelfth International Congress of Chemotherapy. Florence Italy 1981."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.2.273"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.6.723"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.32.1319"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.4.743"},{"key":"e_1_2_1_25_2","first-page":"139","article-title":"In vitro and in vivo microbiological evaluations of cefoperazone","volume":"3","author":"Renzini G","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.2.226"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.4.583"},{"key":"e_1_2_1_28_2","first-page":"24","article-title":"Microbiological studies on cefoperazone","volume":"3","author":"Kayser FH.","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_29_2","first-page":"117","article-title":"JA. Activities of cefoperazone, cefotaxime, cefuroxime, and cephalothin against 128 clinical isolates","volume":"3","author":"Garcia\u2010Rodriguez","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_30_2","first-page":"130","article-title":"In vitro activity of cefoperazone against clinical isolates of enterobacteriaceae, Pseudomonas and Staphylococcus","volume":"3","author":"Olarte J.","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_31_2","unstructured":"ThornsberryC BarryAL JonesRN.Antimicrobial activity of cefoperazone a new wide spectrum cephalosporin (abstract C\u2010177). In: Abstracts of the annual meeting of American Society for Microbiology. Miami Beach 1980."},{"key":"e_1_2_1_32_2","unstructured":"TarpayMM WelchDF MarksMI.In vitro susceptibility of penicillin resistant relatively resistant and susceptible strains of Streptococcus Pneumoniae to moxalactam and cefoperazone (abstract A47). In: Abstracts of the annual meeting of the American Society for Microbiology. Dallas 1981."},{"key":"e_1_2_1_33_2","unstructured":"HellmannFG Rozenberg\u2010ArskaM VerhoefJ.In vitro antibacterial activity of 8 cephalosporins compared with that of moxalactam 4 aminoglycosides and 2 ureido penicillins (abstract 301). See reference 19."},{"key":"e_1_2_1_34_2","unstructured":"Rubio\u2010CalvoMC Gomez\u2010LusR.In vitro antibacterial activity of cefoperazone & LY 127935 against aerobic isolates (abstract 126). In: Program and abstracts of 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston 1979."},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90813-8"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.3.407"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.4.757"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.3.393"},{"key":"e_1_2_1_39_2","first-page":"98","article-title":"Comparative activity of cefoperazone against selected cephalosporinase\u2010producing enteric bacteria","volume":"3","author":"Chabbert YA","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_40_2","first-page":"145","article-title":"Inhibitory concentrations of cefoperazone, cefazolin, cefamandole, cephaloridine, and cefoxitin, for 300 gram\u2010negative clinical isolates","volume":"3","author":"Trabulsi LR","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_41_2","unstructured":"FileTM SalstromSJ TanLet al.Activity of cefoperazone cefotaxime and moxalactam against cephalothin resistant gram\u2010negative bacilli (abstract A 44). See reference 31."},{"key":"e_1_2_1_42_2","unstructured":"OsterCN DobekAS CrossASet al.In vitro activity of cefotaxime moxalactam cefoperazone and piperacillin against multiply antibiotic resistant gram\u2010negative bacteria (abstract A 45). See reference 31."},{"key":"e_1_2_1_43_2","unstructured":"FassRJ.In vitro activity of cefoperazone (T\u20101551) against nonfermenters and Aeromonas hydrophilia (abstract A 46). See reference 31."},{"key":"e_1_2_1_44_2","unstructured":"HindlerJ KurtzTO WinstonDJet al.Comparative in vitro activity of cefoperazone cefotaxime lactamoxen (LY 127935) and piperacillin against gram\u2010negative bacilli (abstract A 48). See reference 31."},{"key":"e_1_2_1_45_2","unstructured":"TragerGM WhiteGW ZimelisVMet al.In vitro comparison of 3 new beta\u2010lactam agents: HR\u2010756 LY\u2010127935 and T\u20101551 (abstract 163). See reference 33."},{"key":"e_1_2_1_46_2","unstructured":"Martinez\u2010BeltranJ LedesmaMA LozaEet al.In vitro activity of the new cephalosporin HR 756 LY 127935 and T\u20101551 (abstract 160). See reference 33."},{"key":"e_1_2_1_47_2","unstructured":"BrodyMV CraigWA KuninCMet al.LY 127935 and cefoperazone Na (T\u20101551): Two beta\u2010lactam antibiotics with anti\u2010pseudomonas activity (abstract 132). See reference 33."},{"key":"e_1_2_1_48_2","unstructured":"WilliamsRJ WilliamsJD.Activity of three cephalosporins and an oxa\u2010beta\u2010lactam against Pseudomonas aeruginosa (abstract 140). See reference 33."},{"key":"e_1_2_1_49_2","first-page":"34","article-title":"Susceptibility of anaerobic bacteria to cefoperazone and other beta\u2010antibiotics","volume":"3","author":"Jacobus NV","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_50_2","unstructured":"JacobusNV GorbachSL TallyFP.Susceptibility of anaerobic bacteria to cefoperazone and other beta\u2010lactam antibiotics (abstract A14). See reference 30."},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.2.129"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.6.957"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.5.683"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.5.600"},{"key":"e_1_2_1_55_2","first-page":"134","article-title":"A study of cefoperazone alone and in combination with tobramycin against Pseudomonas aerugiosa","volume":"3","author":"Pavillard ER","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/7.3.287"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.332"},{"key":"e_1_2_1_58_2","unstructured":"GumpD CrosbyM.Susceptibility of Bacteroides sp. to cefoperazone combined with CP\u201045 899 and related to beta\u2010lactamase production (abstract 762). See reference 19."},{"key":"e_1_2_1_59_2","unstructured":"BauernfeindA.The combined action of cefoperazone and aminoglycosides on gram\u2010negative bacteria (abstract 406). See reference 19."},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.1.63"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.2.239"},{"key":"e_1_2_1_62_2","unstructured":"CrosbyM GumpDW.Activity of cefoperazone alone and combined with beta\u2010lactamase inhibitors or EDTA against Bacteroides sp. (abstract 130). See reference 14."},{"key":"e_1_2_1_63_2","unstructured":"LagastH KlasterskyJ.Comparative study of serum bactericidal activity of cefoperazone cefoperazone plus amikacin and cefoperazone plus mezlocillin against gram\u2010negative bacilli and S. aureus (abstract 752). See reference 14."},{"key":"e_1_2_1_64_2","unstructured":"CraigWA GreenfieldRA GerberAU.Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function (abstract). See reference 3."},{"key":"e_1_2_1_65_2","first-page":"46","article-title":"Single\u2010dose pharmacokinetics of cefoperazone following intravenous administration","volume":"3","author":"Craig WA","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_66_2","first-page":"50","article-title":"Cefoperazone. Pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats","volume":"3","author":"Balant L","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_67_2","first-page":"60","article-title":"Cefoperazone: Absorption, excretion, distribution and metabolism","volume":"3","author":"Shimizu K.","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_68_2","first-page":"80","article-title":"Comparative pharmacokinetics of cefoperazone and cefotaxime","volume":"3","author":"Lode H","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.298"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.6.1037"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.33.625"},{"key":"e_1_2_1_72_2","unstructured":"BundtzenR CraigW ToothakerRet al.Cefoperazone: Single dose pharmacokinetics (abstract 112). In: Program and Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans 1980."},{"key":"e_1_2_1_73_2","unstructured":"ReevesDS BywaterMJ HoltHAet al.Pharmacokinetics of cefoperazone in man (abstract 113). See reference 71."},{"key":"e_1_2_1_74_2","unstructured":"MankoMA GreeneNA MichelsonEL.Pharmacokinetics of cefoperazone Na in comparison to cefamandole nafate and cefazolin Na after IM injection (abstract A 79). See reference 31."},{"key":"e_1_2_1_75_2","unstructured":"FraschiniF BragaPC CeccarelliGet al.Single and multiple dose pharmacokinetics and tissue levels following IM administration of cefoperazone (abstract 407). See reference 19."},{"key":"e_1_2_1_76_2","unstructured":"RichmondJD ScheldWM SpykerDAet al.Pharmacokinetics of cefoperazone in patients on hemodialysis (abstract 754). See reference 14."},{"key":"e_1_2_1_77_2","unstructured":"KleinJO.The pharmacokinetics of cefoperazone in neonates infants and children (abstract). See reference 3."},{"key":"e_1_2_1_78_2","unstructured":"RosenfeldW BathejaR JhaveriRet al.Pharmacokinetics of cefoperazone in neonates (abstract 758). See reference 14."},{"key":"e_1_2_1_79_2","first-page":"139","article-title":"Pharmacokinetics of cefoperazone in neonates after a single intravenous dose (abstract 411). See microbiological evaluations of cefoperazone","volume":"3","author":"Anderson EL","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_80_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1128\/AAC.20.2.226","article-title":"Comparative in vitro study of new cephalosporins","volume":"20","author":"Bodey GP","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_81_2","first-page":"583","article-title":"Antibacterial activity of ceftizoxime, a beta\u2010lactamase\u2010stable cephalosporin","volume":"17","author":"Fu KP","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_82_2","first-page":"24","article-title":"Microbiological studies on cefoperazone","volume":"3","author":"Kayser FH.","journal-title":"Clin Ther."},{"key":"e_1_2_1_83_2","first-page":"117","article-title":"Activities of cefoperazone, cefotaxime, cefuroxime, and cephalothin against 128 clinical isolates","volume":"3","author":"Garcia\u2010Rodriguez JA.","journal-title":"Clin Ther."},{"key":"e_1_2_1_84_2","first-page":"130","article-title":"In vitro activity of cefoperazone against clinical isolates of enterobacteriaceae, Pseudomonas and Staphylococcus","volume":"3","author":"Olarte J.","journal-title":"Clin Ther."},{"key":"e_1_2_1_85_2","unstructured":"ThornsberryC BarryAL JonesRN.Antimicrobial activity of cefoperazone a new wide spectrum cephalosporin (abstract C\u2010177). In: Abstracts of the annual meeting of American Society for Microbiology. Miami Beach 1980."},{"key":"e_1_2_1_86_2","unstructured":"TarpayMM WelchDF MarksMI.In vitro susceptibility of penicillin resistant relatively resistant and susceptible strains of Streptococcus Pneumoniae to moxalactam and cefoperazone (abstract A47). In: Abstracts of the annual meeting of the American Society for Microbiology. Dallas 1981."},{"key":"e_1_2_1_87_2","unstructured":"HeilmannFG Rozenberg\u2010ArskaM VerhoefJ.In vitro antibacterial activity of 8 cephalosporins compared with that of moxalactam 4 aminoglycosides and 2 ureido penicillins (abstract 301). See reference 19."},{"key":"e_1_2_1_88_2","unstructured":"Rubio\u2010CalvoMC Gomez\u2010LusR.In vitro antibacterial activity of cefoperazone & LY 127935 against aerobic isolates (abstract 126). In: Program and abstracts of 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston 1979."},{"issue":"8244","key":"e_1_2_1_89_2","first-page":"477","article-title":"Enterococcal sensitivity to third generation cephalosporins (letter)","volume":"2","author":"File TM","journal-title":"Lancet."},{"key":"e_1_2_1_90_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1128\/AAC.19.3.407","article-title":"Comparison of in vitro activities of eight beta\u2010lactamasestable cephalosporins against beta\u2010lactamase\u2010producing gram\u2010negative bacilli","volume":"19","author":"Verbist L.","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_91_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/AAC.17.4.757","article-title":"In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY 127935), azlocillin, mezlocillin, and other beta\u2010lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta\u2010lactamase\u2010producing strains","volume":"17","author":"Baker CN","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_92_2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.17.3.393","article-title":"Effect of inoculum size and beta\u2010lactamase production on in vitro activity of new cephalosporins against Haemophilus species","volume":"17","author":"Bulger RR","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_93_2","first-page":"98","article-title":"Comparative activity of cefoperazone against selected cephalosporinase\u2010producing enteric bacteria","volume":"3","author":"Chabbert YA","journal-title":"Clin Ther."},{"key":"e_1_2_1_94_2","first-page":"145","article-title":"Inhibitory concentrations of cefoperazone, cefazolin, cefamandole, cephaloridine, and cefoxitin, for 300 gram\u2010negative clinical isolates","volume":"3","author":"Trabulsi LR","journal-title":"Clin Ther."},{"key":"e_1_2_1_95_2","unstructured":"FileTM SalstromSJ TanLet al.Activity of cefoperazone cefotaxime and moxalactam against cephalothin resistant gram\u2010negative bacilli (abstract A 44). See reference 31."},{"key":"e_1_2_1_96_2","unstructured":"OsterCN DobekAS CrossASet al.In vitro activity of cefotaxime moxalactam cefoperazone and piperacillin against multiply antibiotic resistant gram\u2010negative bacteria (abstract A 45). See reference 31."},{"key":"e_1_2_1_97_2","unstructured":"FassRJ.In vitro activity of cefoperazone (T\u20101551) against nonfermenters and Aeromonas hydrophilia (abstract A 46). See reference 31."},{"key":"e_1_2_1_98_2","unstructured":"HindlerJ KurtzTO WinstonDJet al.Comparative in vitro activity of cefoperazone cefotaxime lactamoxen (LY 127935) and piperacillin against gram\u2010negative bacilli (abstract A 48). See reference 31."},{"key":"e_1_2_1_99_2","unstructured":"TragerGM WhiteGW ZimelisVMet al.In vitro comparison of 3 new beta\u2010lactam agents: HR\u2010756 LY\u2010127935 and T\u20101551 (abstract 163). See reference 33."},{"key":"e_1_2_1_100_2","unstructured":"Martinez\u2010BeltranJ LedesmaMA LozaEet al.In vitro activity of the new cephalosporin HR 756 LY 127935 and T\u20101551 (abstract 160). See reference 33."},{"key":"e_1_2_1_101_2","unstructured":"BrodyMV CraigWA KuninCMet al.LY 127935 and cefoperazone Na (T\u20101551): Two beta\u2010lactam antibiotics with anti\u2010pseudomonas activity (abstract 132). See reference 33."},{"key":"e_1_2_1_102_2","unstructured":"WilliamsRJ WilliamsJD.Activity of three cephalosporins and an oxa\u2010beta\u2010lactam against Pseudomonas aeruginosa (abstract 140). See reference 33."},{"key":"e_1_2_1_103_2","first-page":"34","article-title":"Susceptibility of anaerobic bacteria to cefoperazone and other beta\u2010antibiotics","volume":"3","author":"Jacobus NV","journal-title":"Clin Ther."},{"key":"e_1_2_1_104_2","unstructured":"JacobusNV GorbachSL TallyFP.Susceptibility of anaerobic bacteria to cefoperazone and other beta\u2010lactam antibiotics (abstract A14). See reference 30."},{"key":"e_1_2_1_105_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1128\/AAC.17.2.129","article-title":"Comparative in vitro activity of 1\u2010oxa\u2010beta\u2010lactam (LY 127935) and cefoperazone with other beta\u2010lactam antibiotics against anaerobic bacteria","volume":"17","author":"Borobio MV","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_106_2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1128\/AAC.17.6.957","article-title":"Susceptibilities of anaerobic bacteria to cefoperazone and other antibiotics","volume":"17","author":"Kaye D","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_107_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1128\/AAC.20.5.683","article-title":"Comparative in vitro activity of ceftizoxime, cefoperazone, and cefoxitin against anaerobic bacteria","volume":"20","author":"Drulak MW","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_108_2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1128\/AAC.20.5.600","article-title":"Comparative in vitro activity of new beta\u2010lactam antibiotics against anaerobic bacteria","volume":"20","author":"Rolfe RD","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_109_2","first-page":"134","article-title":"A study of cefoperazone alone and in combination with tobramycin against Pseudomonas aerugiosa","volume":"3","author":"Pavillard ER","journal-title":"Clin Ther."},{"key":"e_1_2_1_110_2","first-page":"287","article-title":"Synergistic activity of cefoperazone in combination with beta\u2010lactamase inhibitors","volume":"7","author":"Fu KP","journal-title":"J Antimicrob Chemother."},{"key":"e_1_2_1_111_2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.19.2.332","article-title":"Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa","volume":"19","author":"Mintz L","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_112_2","unstructured":"GumpD CrosbyM.Susceptibility of Bacteroides sp. to cefoperazone combined with CP\u201045 899 and related to beta\u2010lactamase production (abstract 762). See reference 19."},{"key":"e_1_2_1_113_2","unstructured":"BauernfeindA.The combined action of cefoperazone and aminoglycosides on gram\u2010negative bacteria (abstract 406). See reference 19."},{"key":"e_1_2_1_114_2","first-page":"63","article-title":"Bacterial activity of cefoperazone with CP\u201045,899 against large inocula of beta\u2010lactamase producing Haemophilus influenza","volume":"20","author":"Yu PK","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_115_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.20.2.239","article-title":"Comparative in vitro synergistic activity of new beta\u2010lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens","volume":"20","author":"Kurtz TO","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_116_2","unstructured":"CrosbyM GumpDW.Activity of cefoperazone alone and combined with beta\u2010lactamase inhibitors or EDTA against Bacteroides sp. (abstract 130). See reference 14."},{"key":"e_1_2_1_117_2","unstructured":"LagastH KlasterskyJ.Comparative study of serum bactericidal activity of cefoperazone cefoperazone plus amikacin and cefoperazone plus mezlocillin against gram\u2010negative bacilli and S. aureus (abstract 752). See reference 14."},{"key":"e_1_2_1_118_2","unstructured":"CraigWA GreenfieldRA GerberAU.Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function (abstract). See reference 3."},{"key":"e_1_2_1_119_2","first-page":"46","article-title":"Single\u2010dose pharmacokinetics of cefoperazone following intravenous administration","volume":"3","author":"Craig WA","journal-title":"Clin Ther."},{"key":"e_1_2_1_120_2","first-page":"50","article-title":"Cefoperazone: Pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats","volume":"3","author":"Balant L","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_121_2","first-page":"60","article-title":"Cefoperazone: Absorption, excretion, distribution and metabolism","volume":"3","author":"Shimizu K.","journal-title":"Clin Ther."},{"key":"e_1_2_1_122_2","first-page":"80","article-title":"Comparative pharmacokinetics of cefoperazone and cefotaxime","volume":"3","author":"Lode H","journal-title":"Clin Ther."},{"key":"e_1_2_1_123_2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/AAC.19.2.298","article-title":"Comparative pharmacokinetics of cefoperazone and cefamandole","volume":"19","author":"Srinivasan S","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_124_2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1128\/AAC.19.6.1037","article-title":"Pharmacokinetics of cefoperazone in patients with neoplastic disease","volume":"19","author":"Maksymuik AW","journal-title":"Antimicrob Agents Chemother."},{"key":"e_1_2_1_125_2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7164\/antibiotics.33.625","article-title":"Studies on protein binding of antibiotics: I. Effect of cefazolin on protein binding and pharmacokinetics of cefoperazone","volume":"33","author":"Watanabe Y","journal-title":"J Antibiot."},{"key":"e_1_2_1_126_2","unstructured":"BundtzenR CraigW ToothakerRet al.Cefoperazone: Single dose pharmacokinetics (abstract 112). In: Program and Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans 1980."},{"key":"e_1_2_1_127_2","unstructured":"ReevesDS BywaterMJ HoltHAet al.Pharmacokinetics of cefoperazone in man (abstract 113). See reference 71."},{"key":"e_1_2_1_128_2","unstructured":"MankoMA GreeneNA MichelsonEL.Pharmacokinetics of cefoperazone Na in comparison to cefamandole nafate and cefazolin Na after IM injection (abstract A 79). See reference 31."},{"key":"e_1_2_1_129_2","unstructured":"FraschiniF BragaPC CeccarelliGet al.Single and multiple dose pharmacokinetics and tissue levels following IM administration of cefoperazone (abstract 407). See reference 19."},{"key":"e_1_2_1_130_2","unstructured":"RichmondJD ScheldWM SpykerDAet al.Pharmacokinetics of cefoperazone in patients on hemodialysis (abstract 754). See reference 14."},{"key":"e_1_2_1_131_2","unstructured":"KleinJO.The pharmacokinetics of cefoperazone in neonates infants and children (abstract). See reference 3."},{"key":"e_1_2_1_132_2","unstructured":"RosenfeldW BathejaR JhaveriRet al.Pharmacokinetics of cefoperazone in neonates (abstract 758). See reference 14."},{"key":"e_1_2_1_133_2","unstructured":"AndersonEL HilligossDM SzegoE.Pharmacokinetics of cefoperazone in neonates after a single intravenous dose (abstract 411). See reference 19."},{"key":"e_1_2_1_134_2","unstructured":"AndersonEL HilligossDM SzegoEet al.Serum and cerebrospinal fluid concentration of cefoperazone in neonates after a single intravenous dose (abstract 759). See reference 14."},{"key":"e_1_2_1_135_2","unstructured":"BurgioGR CaredduP MartiniAet al.First European experience with the pediatric use of cefoperazone: Clinical and blood levels data (abstract 412). See reference 19."},{"key":"e_1_2_1_136_2","unstructured":"GordonAJ PhyfferoenM.Cefoperazone sodium in the treatment of serious bacterial infections in 2 100 adults and children: Multi\u2010center trials in Europe Latin America and Australasia (abstract). See reference 3."},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.20.6.783"},{"key":"e_1_2_1_138_2","unstructured":"AxelrodJL KochmanRS.Cefoperazone concentrations in human aqueous humor (abstract 757). See reference 14."},{"key":"e_1_2_1_139_2","unstructured":"OwensN FrenchM KlimekJet al.Pharmacokinetics of cefoperazone in normal and critically ill patients (abstract 764). See reference 19."},{"key":"e_1_2_1_140_2","unstructured":"CostanzoE FalsaperlaA PennisiGet al.Cefoperazone: Blood and CSF levels in patients with inflamed and noninflamed HEB (abstract 763). See reference 19."},{"key":"e_1_2_1_141_2","unstructured":"AyarraJ Garcia\u2010IglesiasMC LoscertalesJet al.Lung tissue concentrations of cefoperazone (abstract 766). See reference 19."},{"key":"e_1_2_1_142_2","unstructured":"WittmannDH SchassanHH SeidelH.Bone concentrations of six new beta\u2010lactam\u2010antibiotics (abstract 410). See reference 19."},{"key":"e_1_2_1_143_2","unstructured":"GallS.Cefoperazone as a prophylactic agent in abdominal hysterectomy (abstract). See reference 3."},{"key":"e_1_2_1_144_2","unstructured":"SchalkhauserK AdamD.Concentrations of cefoperazone in various tissues of the urogenital system (abstract 409). See reference 19."},{"key":"e_1_2_1_145_2","unstructured":"ShimizuK.Absorption excretion distribution and metabolism (table p. 81). In: The 27th General Congress of Japan Society of Chemotherapy: New Drug Symposium IT\u20101551. Fukuoka City Japan 1979."},{"key":"e_1_2_1_146_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.6.980"},{"key":"e_1_2_1_147_2","unstructured":"DucrouxA PothierP PortierH.Cefoperazone levels in the human biliary tract (abstract 115). See reference 71."},{"key":"e_1_2_1_148_2","unstructured":"KemmerichB LodeH BornerKet al.Biliary excretion of cefoperazone in humans (abstract 767). See reference 19."},{"key":"e_1_2_1_149_2","unstructured":"RosenfeldMB RatzanKR LauredoI.A comparison of the biliary tract excretion of cefoperazone and cefamandole (abstract 114). See reference 71."},{"key":"e_1_2_1_150_2","unstructured":"ChandesrisC KazmierczakA FavreJPet al.Concentrations of cefoperazone in bile and gall bladder wall after 1g or 2g intravenous administration (abstract 408). See reference 19."},{"key":"e_1_2_1_151_2","unstructured":"WheelerLA KaplowitzN FinegoldSM.Pharmacokinetic study of cefoperazone and metabolites in patients with liver disease (abstract 755). See reference 14."},{"key":"e_1_2_1_152_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198100221-00011"},{"key":"e_1_2_1_153_2","first-page":"857","article-title":"Behavior of cefoperazone (a new cephalosporin) in man (abstract)","volume":"17","author":"Dayer P","year":"1980","journal-title":"Kidney Int."},{"key":"e_1_2_1_154_2","unstructured":"DeRosaF PalmumboM CataronelliLet al.Kinetic data in acute hepatitis and chronic renal insufficiency patients and clinical results after use of cefoperazone (abstract 765). See reference 19."},{"key":"e_1_2_1_155_2","unstructured":"CraigWA GreenfieldR GoetzMet al.Pharmacokinetics of cefoperazone in hepatic dysfunction (abstract 756). See reference 14."},{"key":"e_1_2_1_156_2","first-page":"159","article-title":"Clinical trials with cefoperazone in the field of internal medicine in Japan","volume":"3","author":"Mashimo K","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_157_2","first-page":"173","article-title":"Clinical trials with cefoperazone in the field of surgery in Japan","volume":"3","author":"Shibata K.","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_158_2","first-page":"190","article-title":"Clinical comparison of cefoperazone in complicated urinary tract infections using a double\u2010blind method","volume":"3","author":"Nishiura T.","year":"1980","journal-title":"Clin Ther."},{"key":"e_1_2_1_159_2","unstructured":"SwarzH.The safety of cefoperazone (abstract). See reference 3."},{"key":"e_1_2_1_160_2","unstructured":"GardnerWG.Multicenter clinical evaluation of cefoperazone in the treatment of lower respiratory tract infections (abstract). See reference 3."},{"key":"e_1_2_1_161_2","unstructured":"FileTM TanJS.Cefoperazone therapy of acute bacterial urinary tract infections: Multicenter noncomparative and comparative studies (abstract). See reference 3."},{"key":"e_1_2_1_162_2","unstructured":"StrausbaughLJ.Results of cefoperazone therapy in obstetrical and gynecological infections (abstract). See reference 3."},{"key":"e_1_2_1_163_2","unstructured":"RosenbergEW.Use of cefoperazone in the empiric treatment of serious skin infections (abstract). See reference 3."},{"key":"e_1_2_1_164_2","unstructured":"BairdI.Multicentered evaluation of cefoperazone sodium in the treatment of patients with intraabdominal infections (abstract). See reference 3."},{"key":"e_1_2_1_165_2","unstructured":"BodeyGP BolivarR FainsteinV.Use of cefoperazone for therapy of infections in cancer patients (abstract). See reference 3."},{"key":"e_1_2_1_166_2","unstructured":"BerneTV YellinAE ApplemanMDet al.Antibiotic management of surgically treated gangrenous or perforated appendicitis: Clinical comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone (abstract). See reference 3."},{"key":"e_1_2_1_167_2","unstructured":"FileTM ShonkRF DuafalaME.Evaluation of cefoperazone in the treatment of lower respiratory tract infections (abstract A 38). See reference 30."},{"key":"e_1_2_1_168_2","unstructured":"StrausbaughLJ KobbermannTW JohnsonRLet al.Cefoperazone therapy of gynecological infections (abstract A 75). See reference 31."},{"key":"e_1_2_1_169_2","unstructured":"GardnerWG.Multicenter clinical evaluation of cefoperazone in treatment of lower respiratory tract infections (abstract 485). See reference 14."},{"key":"e_1_2_1_170_2","unstructured":"FileTM TanJS.Cefoperazone therapy of acute bacterial urinary tract infections: Multicenter noncomparative and comparative studies (abstract 486). See reference 14."},{"key":"e_1_2_1_171_2","unstructured":"FileTM GardnerW TanJSet al.A randomized comparative study of cefoperazone and cefamandole in the treatment of acute bacterial lower respiratory tract infections (abstract 479). See reference 14."},{"key":"e_1_2_1_172_2","unstructured":"StambolianD JasovichA CorheyC.In vitro evaluation of cefoperazone and clinical use in complicated urinary tract infections (abstract 760). See reference 19."},{"key":"e_1_2_1_173_2","unstructured":"HeseltinePNR ApplemanMD PlattLD.Clinical efficacy of cefoperazone therapy in gentamicin and cephalothin resistant and susceptible infections (abstract 475). See reference 14."},{"key":"e_1_2_1_174_2","unstructured":"BolivarR FainsteinV BodeyGPet al.Cefoperazone therapy of infections in cancer patients (abstract 476). See reference 14."},{"key":"e_1_2_1_175_2","unstructured":"BairdI BurginM KoseRet al.Treatment of hospitalized patients with cefoperazone sodium (abstract 118). See reference 71."},{"key":"e_1_2_1_176_2","unstructured":"BreyerS GraningerW SchmidbauerC.Clinical experience and in vitro activity of cefoperazone against cephalothin resistant organisms (abstract 414). See reference 19."},{"key":"e_1_2_1_177_2","unstructured":"GlaserJB ManiatasT CastellanoM.Comparative evaluation of cefoperazone vs. cefamandole for the treatment of lower respiratory tract infection (abstract 478). See reference 14."},{"key":"e_1_2_1_178_2","unstructured":"BairdI.Multicentered evaluation of cefoperazone for the treatment of patients with intraabdominal infections (abstract 482). See reference 14."},{"key":"e_1_2_1_179_2","unstructured":"StrausbaughLJ.Cefoperazone therapy of obstetrical and gynecological infections (abstract 483). See reference 14."},{"key":"e_1_2_1_180_2","unstructured":"FinegoldSM.Multicenter trial of cefoperazone in infections of skin soft tissue bone and joints (abstract 484). See reference 14."},{"key":"e_1_2_1_181_2","unstructured":"EcholsR CondoluciD AndrewsBet al.Cefoperazone treatment of skin and skin structures (abstract 761). See reference 14."},{"key":"e_1_2_1_182_2","unstructured":"SarverDK ChristensenGD HesterMG.Clinical and laboratory evaluation of cefoperazone (abstract 116). See reference 71."},{"key":"e_1_2_1_183_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/9.3.223"},{"key":"e_1_2_1_184_2","first-page":"757","article-title":"Clinical evaluation of cefoperazone in the treatment of urinary tract infections in geriatric patients","volume":"27","author":"Vryens R","year":"1980","journal-title":"Curr Ther Res."},{"key":"e_1_2_1_185_2","unstructured":"AlestigK CarlbergH NordCEet al.Intestinal side effects of cefoperazone in healthy subjects and patients (abstract 753). See reference 14."},{"key":"e_1_2_1_186_2","unstructured":"MillerH WarrenJ DiFrancoDet al.A controlled trial of cefoperazone vs. cefamandole\/tobramycin in serious gram\u2010negative rod infections (abstract 477). See reference 14."},{"key":"e_1_2_1_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)91868-1"},{"key":"e_1_2_1_188_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1980.03300490015010"},{"key":"e_1_2_1_189_2","first-page":"858","article-title":"Disulfiram\u2010like reaction associated with a parenteral cephalosporin","volume":"37","author":"Foster TS","year":"1980","journal-title":"Am J Hosp Pharm."},{"key":"e_1_2_1_190_2","unstructured":"WarrenJW MillerEH DiFrancoDEet al.A prospective randomized comparison of cefoperazone versus the combination of cefamandole and tobramycin in the treatment of serious gram\u2010negative infections (abstract). See reference 3."},{"key":"e_1_2_1_191_2","unstructured":"AlestigK CarlbergH TrollforsB.Clinical effect of cefoperazone in patients with acute severe infections (abstract 760). See reference 14."},{"key":"e_1_2_1_192_2","unstructured":"TempleJ HolmesB PollockBet al.Cefoperazone in the treatment of serious infections (abstract 117). See reference 71."},{"key":"e_1_2_1_193_2","unstructured":"PerlinoC LichtenbergerC.Cefoperazone vs. procaine penicillin G treatment of pneumococcal pneumonia (abstract 480). See reference 14."},{"key":"e_1_2_1_194_2","unstructured":"Rubio\u2010CalvoMCR FernandezFJ AguirreFRet al.Cefoperazone in the treatment of urinary tract infections (abstract 768). See reference 19."},{"key":"e_1_2_1_195_2","first-page":"193","article-title":"Cefoxitin: single\u2010agent treatment of mixed aerobic\u2010anaerobic pelvic infections","volume":"54","author":"Sweet RL","year":"1979","journal-title":"Obstet Gynecol."},{"key":"e_1_2_1_196_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(79)90005-X"},{"key":"e_1_2_1_197_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0002-9378(16)33026-5","article-title":"A comparison of clindamycin\u2010gentamicin and penicillin\u2010gentamicin in the treatment of post\u2010cesarean section endometritis","volume":"134","author":"DiZerega G","year":"1979","journal-title":"Am J Obstet Gynecol."},{"key":"e_1_2_1_198_2","unstructured":"MongsV OrdenB.Treatment of food handlers typhoid carriers with a single dose of cefamandole or cefoperazone (abstract 305). See reference 19."},{"key":"e_1_2_1_199_2","unstructured":"GallS.Cefoperazone as a prophylactic agent in abdominal hysterectomy (abstract 413). See reference 19."},{"key":"e_1_2_1_200_2","unstructured":"RaabTA BhayanaJ BaldermanSet al.Comparison of cefoperazone and cephalothin in prophylaxis of coronary artery bypass graft surgery (abstract 481). See reference 14."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1982.tb03186.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1875-9114.1982.tb03186.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1875-9114.1982.tb03186.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:57:21Z","timestamp":1761047841000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/j.1875-9114.1982.tb03186.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,7,8]]},"references-count":199,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1982,7,8]]}},"alternative-id":["10.1002\/j.1875-9114.1982.tb03186.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1875-9114.1982.tb03186.x","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[1982,7,8]]},"assertion":[{"value":"2012-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}